Anish Patel - Jan 7, 2025 Form 4 Insider Report for Enliven Therapeutics, Inc. (ELVN)

Role
CHIEF OPERATING OFFICER
Signature
/s/ Ben Hohl, by power of attorney
Stock symbol
ELVN
Transactions as of
Jan 7, 2025
Transactions value $
-$646,604
Form type
4
Date filed
1/10/2025, 05:31 PM
Previous filing
Oct 22, 2024
Next filing
Feb 10, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ELVN Common Stock Options Exercise $12K +10.7K $1.12 10.7K Jan 7, 2025 Direct F1
transaction ELVN Common Stock Options Exercise $4.96K +2K +18.69% $2.48 12.7K Jan 7, 2025 Direct F1
transaction ELVN Common Stock Options Exercise $22.3K +9K +70.87% $2.48 21.7K Jan 7, 2025 Direct F1
transaction ELVN Common Stock Sale -$489K -20.3K -93.36% $24.15 1.44K Jan 7, 2025 Direct F1, F2
transaction ELVN Common Stock Sale -$35.4K -1.44K -100% $24.56 0 Jan 7, 2025 Direct F1, F3
transaction ELVN Common Stock Sale -$159K -6.58K -1.92% $24.17 337K Jan 7, 2025 See footnote F1, F4, F5
transaction ELVN Common Stock Sale -$2.21K -90 -0.03% $24.60 337K Jan 7, 2025 See footnote F1, F5, F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELVN Employee Stock Option (right to buy) Options Exercise $0 -10.7K -99.38% $0.00 67 Jan 7, 2025 Common Stock 10.7K $1.12 Direct F1, F7
transaction ELVN Employee Stock Option (right to buy) Options Exercise $0 -2K -70.75% $0.00 827 Jan 7, 2025 Common Stock 2K $2.48 Direct F1, F7
transaction ELVN Employee Stock Option (right to buy) Options Exercise $0 -9K -16.87% $0.00 44.3K Jan 7, 2025 Common Stock 9K $2.48 Direct F1, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on September 30, 2024 by the Reporting Person and by The Patel / Dong Family Trust Dated August 24, 2017, for which the Reporting Person serves as trustee (the "Patel / Dong Family Trust").
F2 This transaction was executed in multiple trades at prices ranging from $23.5364 to $24.535. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3 This transaction was executed in multiple trades at prices ranging from $24.54 to $24.63. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F4 This transaction was executed in multiple trades at prices ranging from $23.595 to $24.585. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F5 The shares are held by The Patel / Dong Family Trust.
F6 This transaction was executed in multiple trades at prices ranging from $24.60 to $24.61. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F7 All of the shares subject to this option are fully vested and exercisable as of the date hereof.
F8 The option, originally for 75,620 shares, vests in 48 equal monthly installments beginning on January 14, 2021.